The U.S. Food and Drug Administration (FDA) is reviewing an application seeking expanded approval of an under-the-skin injection version of Leqembi (lecanemab), called Leqembi Iqlik. Leqembi is an ...

Subcutaneous (SC) formulations of monoclonal antibodies are rapidly transforming the delivery of cancer immunotherapy. Designed to replace or complement intravenous (IV) administration, SC delivery ...

The FDA granted accelerated approval to mosunetuzumab (Lunsumio; Genentech), a CD20/CD3 bispecific T-cell engager administered as a subcutaneous injection for patients with relapsed or refractory ...

Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio amid competition among CD20xCD3 bispecific antibodies. The FDA has approved ...

The subcutaneous formulation of amivantamab reduces administration time and systemic reactions compared to the intravenous version. PALOMA-3 trial results showed noninferiority in pharmacokinetics and ...

You may want to lose body fat but might not know exactly where fat is stored in your body. That’s when knowing the difference between subcutaneous fat and visceral fat can be handy. The main ...

According to Lilly, the single-injection, citrate-free, maintenance dose will be available in the US as a prefilled pen or prefilled syringe in early 2026. The Food and Drug Administration (FDA) has ...

Merck's Keytruda Qlex offers a groundbreaking subcutaneous cancer treatment, enhancing patient convenience with faster administration and broader access to immunotherapy. The FDA approved Merck’s ...

Tremfya is now the first and only fully subcutaneous IL-23 inhibitor approved to treat both ulcerative colitis and Crohn’s disease. The FDA has approved a subcutaneous injection induction regimen of ...

For the last two years, Keytruda has reigned as the world’s top-selling drug—a distinction under threat with key patent protections expiring in 2028. The FDA has approved a subcutaneous version of ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...